PARP1 and breast carcinoma: We previously published that mtp53 interacts with PARP1 in breast cancer cells and that mtp53 expression increases cancer cell sensitivity to combination PARP inhibitor (PARPi) talazoparib (Tal) with temozolomide (Temo) treatment [22, 23, 54, 55].